Cargando…
PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
Thiazolidinediones (TZDs) are selective agonists of the peroxisome proliferator-activated receptor (PPAR) gamma, a transcription factor belonging to the superfamily of nuclear hormone receptors. Although activation of PPARγ by TZDs has been best characterized by its ability to regulate expression of...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396217/ https://www.ncbi.nlm.nih.gov/pubmed/18509487 http://dx.doi.org/10.1155/2008/547470 |
_version_ | 1782155546919436288 |
---|---|
author | Lichtor, Terry Spagnolo, Alessandra Glick, Roberta P. Feinstein, Douglas L. |
author_facet | Lichtor, Terry Spagnolo, Alessandra Glick, Roberta P. Feinstein, Douglas L. |
author_sort | Lichtor, Terry |
collection | PubMed |
description | Thiazolidinediones (TZDs) are selective agonists of the peroxisome proliferator-activated receptor (PPAR) gamma, a transcription factor belonging to the superfamily of nuclear hormone receptors. Although activation of PPARγ by TZDs has been best characterized by its ability to regulate expression of genes associated with lipid metabolism, PPARγ agonists have other physiological effects including modulating pro- and anti-inflammatory gene expression and inducing apoptosis in several cell types including glioma cells and cell lines. Immunotherapeutic approaches to reducing brain tumors are focused on means to reduce the immunosuppressive responses of tumors which dampen the ability of cytotoxic T-lymphocytes to kill tumors. Initial studies from our lab show that combination of an immunotherapeutic strategy with TZD treatment provides synergistic benefit in animals with implanted tumors. The potential of this combined approach for treatment of brain tumors is reviewed in this report. |
format | Text |
id | pubmed-2396217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-23962172008-05-28 PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors Lichtor, Terry Spagnolo, Alessandra Glick, Roberta P. Feinstein, Douglas L. PPAR Res Review Article Thiazolidinediones (TZDs) are selective agonists of the peroxisome proliferator-activated receptor (PPAR) gamma, a transcription factor belonging to the superfamily of nuclear hormone receptors. Although activation of PPARγ by TZDs has been best characterized by its ability to regulate expression of genes associated with lipid metabolism, PPARγ agonists have other physiological effects including modulating pro- and anti-inflammatory gene expression and inducing apoptosis in several cell types including glioma cells and cell lines. Immunotherapeutic approaches to reducing brain tumors are focused on means to reduce the immunosuppressive responses of tumors which dampen the ability of cytotoxic T-lymphocytes to kill tumors. Initial studies from our lab show that combination of an immunotherapeutic strategy with TZD treatment provides synergistic benefit in animals with implanted tumors. The potential of this combined approach for treatment of brain tumors is reviewed in this report. Hindawi Publishing Corporation 2008 2008-05-22 /pmc/articles/PMC2396217/ /pubmed/18509487 http://dx.doi.org/10.1155/2008/547470 Text en Copyright © 2008 Terry Lichtor et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lichtor, Terry Spagnolo, Alessandra Glick, Roberta P. Feinstein, Douglas L. PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title | PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title_full | PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title_fullStr | PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title_full_unstemmed | PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title_short | PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors |
title_sort | ppar-γ thiazolidinedione agonists and immunotherapy in the treatment of brain tumors |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396217/ https://www.ncbi.nlm.nih.gov/pubmed/18509487 http://dx.doi.org/10.1155/2008/547470 |
work_keys_str_mv | AT lichtorterry ppargthiazolidinedioneagonistsandimmunotherapyinthetreatmentofbraintumors AT spagnoloalessandra ppargthiazolidinedioneagonistsandimmunotherapyinthetreatmentofbraintumors AT glickrobertap ppargthiazolidinedioneagonistsandimmunotherapyinthetreatmentofbraintumors AT feinsteindouglasl ppargthiazolidinedioneagonistsandimmunotherapyinthetreatmentofbraintumors |